Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Research & Development (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Research & Development for 10 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 30.04% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.3 million, a 5.22% increase, with the full-year FY2025 number at $6.3 million, up 5.22% from a year prior.
  • Research & Development was $1.7 million for Q4 2025 at Niagen Bioscience, down from $1.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.1 million in Q1 2024 to a low of $787000.0 in Q1 2021.
  • A 5-year average of $1.3 million and a median of $1.3 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 75.61% in 2024, then tumbled 39.95% in 2025.
  • Niagen Bioscience's Research & Development stood at $1.0 million in 2021, then rose by 22.39% to $1.3 million in 2022, then decreased by 9.38% to $1.2 million in 2023, then grew by 13.46% to $1.3 million in 2024, then surged by 30.04% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Research & Development are $1.7 million (Q4 2025), $1.8 million (Q3 2025), and $1.6 million (Q2 2025).